ArticleAtherosclerosis plus2026
Retinal findings in familial hypercholesterolemia: An exploratory case-control study.
Article in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Patients with familial hypercholesterolemia (FH) have elevated LDL-C levels from birth and increased risk of cardiovascular disease due to atherosclerosis, mostly affecting larger arteries. Less is known about effects of elevated LDL-cholesterol on smaller arteries. Retinal arterioles are prone to damage in the form of stiffening and thickening. We therefore explored the occurrence of retinal arteriolosclerosis in patients with genetically verified FH, and in a control group. Associations between retinal arteriolosclerosis and current serum lipid values, sex, age, statin treatment, and years on lipid-lowering treatment were also investigated. Methods: Eligible patients were 40 to 70 years of age, normotensive, and non-smokers. Exclusion criteria were diabetes and vascular retinal disease. Control subjects had to have normal lipid levels and no history of cardiovascular disease. Lipid measurements were collected prior to the visit, and at the visit retinal fundus photographs of both eyes were taken. The fundus photographs were graded by two ophthalmologists according to the Scheie classification for retinal arteriolosclerosis. Results: Fifty patients with FH and 30 control subjects participated. Mean duration of lipid-lowering medication for the patient group was 17.0 years. The control group had higher total cholesterol, LDL-C and HDL-C, ApoB and ApoA1 levels than the patient group. There were no differences in the occurrence of retinal arteriolosclerosis between the two groups, and no associations were found between current lipid levels, age, sex, statin treatment, years on LLT and retinal arteriolosclerosis. Conclusion: Patients with FH did not have increased prevalence of retinal arteriolosclerosis compared to controls.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.